WO2000072757A1 - Surface stabilized microbubbles for use in ultrasound contrast and drug delivery agents - Google Patents
Surface stabilized microbubbles for use in ultrasound contrast and drug delivery agents Download PDFInfo
- Publication number
- WO2000072757A1 WO2000072757A1 PCT/US2000/015161 US0015161W WO0072757A1 WO 2000072757 A1 WO2000072757 A1 WO 2000072757A1 US 0015161 W US0015161 W US 0015161W WO 0072757 A1 WO0072757 A1 WO 0072757A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gas
- microparticle
- microbubble
- liquid
- produced
- Prior art date
Links
- 238000002604 ultrasonography Methods 0.000 title claims abstract description 13
- 238000012377 drug delivery Methods 0.000 title abstract description 8
- 229940124447 delivery agent Drugs 0.000 title abstract description 5
- 239000011859 microparticle Substances 0.000 claims abstract description 51
- 230000005661 hydrophobic surface Effects 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000007789 gas Substances 0.000 description 40
- 239000002245 particle Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 10
- 239000002872 contrast media Substances 0.000 description 9
- 239000002961 echo contrast media Substances 0.000 description 8
- 239000004094 surface-active agent Substances 0.000 description 8
- 239000004698 Polyethylene Substances 0.000 description 7
- 230000002209 hydrophobic effect Effects 0.000 description 7
- -1 polyethylene Polymers 0.000 description 7
- 229920000573 polyethylene Polymers 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 229910018503 SF6 Inorganic materials 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- WRQGPGZATPOHHX-UHFFFAOYSA-N ethyl 2-oxohexanoate Chemical compound CCCCC(=O)C(=O)OCC WRQGPGZATPOHHX-UHFFFAOYSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 240000007930 Oxalis acetosella Species 0.000 description 2
- 235000008098 Oxalis acetosella Nutrition 0.000 description 2
- 229920006926 PFC Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229940068984 polyvinyl alcohol Drugs 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- SFZCNBIFKDRMGX-UHFFFAOYSA-N sulfur hexafluoride Chemical compound FS(F)(F)(F)(F)F SFZCNBIFKDRMGX-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 description 1
- 229960004647 iopamidol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229910052756 noble gas Inorganic materials 0.000 description 1
- 150000002835 noble gases Chemical class 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000010363 phase shift Effects 0.000 description 1
- GVKCHTBDSMQENH-UHFFFAOYSA-L phloxine B Chemical compound [Na+].[Na+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 GVKCHTBDSMQENH-UHFFFAOYSA-L 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 1
- 229940082004 sodium laurate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960000909 sulfur hexafluoride Drugs 0.000 description 1
- 238000010809 targeting technique Methods 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/225—Microparticles, microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/48—Diagnostic techniques
- A61B8/481—Diagnostic techniques involving the use of contrast agent, e.g. microbubbles introduced into the bloodstream
Definitions
- Ultrasound contrast agents are used routinely in medical diagnostic, as well as industrial, ultrasound.
- contrast agents are usually gas bubbles, which derive their contrast properties from the large acoustic impedance mismatch between blood and the gas contained therein.
- Important parameters for the contrast agent include particle size, imaging frequency, density, compressibility, particle behavior (surface tension, internal pressure, bubble-like qualities), and biodistribution and tolerance.
- Bubbles of these dimensions have resonance frequencies in the diagnostic ultrasonic range, thus improving their backscatter enhancement capabilities. Sonication has been found to be a reliable and reproducible technique for preparing standardized echo contrast agent solutions containing uniformly small microbubbles. Bubbles generated via this technique typically range in size from 1 to 15 microns in diameter with a mean bubble diameter of 6 microns (Keller et al . J. Ul trasound Med. 1986 5(9):493-8). However, the durability of these bubbles in the blood stream has been found to be limited, providing impetus for a number of approaches to further stabilize them.
- the half -life of free microbubble solutions has been reported to range from 44 ⁇ 12 seconds for Hypaque 50%, to 253 ⁇ 73 seconds for Iopamidol .
- Addition of a surfactant to dextrose 70 wt% has been reported to prolong bubble half life from 58 ⁇ 12 seconds to 1018 ⁇ 276 seconds (Keller et al . J " . Ul trasound Med . 1986 5(9) :493-8) .
- WO 9847540 discloses a contrast agent for diagnostic ultrasound and targeted disease imaging and drug delivery comprising a dispersion of a biocompatible azeotropic mixture, which contains a halocarbon.
- WO 9729783 discloses a material useful as a contrast agent which comprises an aqueous dispersion of gas microbubbles stabilized by amphiphilic material containing phospholipid molecules having an overall net charge.
- U.S. Patent 5,695,740, U.S. Patent 5,567,415 and U.S. Patent 5,701,899 disclose a pharmaceutically acceptable ultrasound contrast agent comprising microbubbles with an internal atmosphere enhanced with a perfluorocarbon gas.
- WO 9421301 discloses an ultrasound agent consisting of a biocompatible oil-in-water emulsion in which the oil phase comprises an oil-soluble gas/fluid or gas precursor.
- U.S. Patent 5,637,289, U.S. Patent 5,648,062, U.S. Patent 5,827,502; and U.S. Patent 5,614,169 disclose contrast agents comprising water-soluble, microbubble generating carbohydrate microparticles, admixed with at least 20% of a non-surface active, less water-soluble material, a surfactant or an amphiphillic organic acid.
- the agent is prepared by dry mixing, or by mixing solutions of components followed by evaporation and micronizing.
- U.S. Patent 5,686,060 describes an injectable suspension for ultrasonic echography comprising a carrier liquid containing at least 10 7 microbubbles per milliliter and at least one saturated phospholipid at a concentration below 0.01% by weight. Also disclosed is a method of producing the suspension of air or gas filled microbubbles which comprises dissolving a surfactant and stabilizer in an organic solvent; freeze drying the solution to form a dry powder; contacting the powder with air or another gas; and admixing the powder with the aqueous carrier.
- EP699445 describes a method of preparing a stable microbubble solution for use as an imaging agent via a surfactant mixture containing a sodium salt of saturated carboxylic acids and saponin, stearic acid, phloxine, crystal violet, polyvinyl alcohol and/or sodium laurate.
- bubbles are formed in an aqueous solution by mixing with a machine having a 0 to 20000 rpm shaft and simultaneously introducing gas.
- the dispersion of microbubbles produced is poured into a stopcock bottomed tube and left to stand.
- the microbubble solution is then collected from the tube bottom and the surfactant mixture is added to change the nature of the bubble surface.
- BR1 Stabilized sulfur hexafluoride (SF 6 ) microbubbles, referred to as BR1, have also been evaluated for use as an echo contrast agent (Schneider et al . Invest. Radiol . 1995 30 (8) :451-7) .
- BR1 is formulated as a lyophilized product, which after addition of saline, provides a suspension containing 2 x 10 8 SF 6 microbubbles/ml with a mean diameter of 2.5 microns.
- the use of SF 6 rather than air provides improved resistance to pressure increases such as those occurring in the left heart during systole. After reconstitution, the echogenicity and bubble characteristics remain almost constant for 8 hours.
- BR1 injections in animals resulted in a homogenous, dose-dependent opacification of the left heart. Accordingly, BR1 is suggested to be a promising ultrasound contrast agent .
- Micrometer-sized porous particles or "nanosponges” with properties suitable for entrapment and stabilization of the gas bubbles due to an irregular complex surface morphology have also been developed.
- the complex morphology and surface chemistry involved in the production of these nanosponges makes it unfeasible to directly measure the volume of entrained gas (Phillips et al . Ul trasonics 1998 36 (8) : 883-892) . Accordingly, a model based on acoustic scattering principles has been proposed which indicates that only a small volume fraction of the gas should be necessary to significantly enhance the echogenicity of this type of particle-based contrast agent.
- the effective scattering cross-section is evaluated as a function of the volume fraction of gas contained in the overall scatterer and the overall scatterer diameter.
- the volume fraction of gas is considered as a discrete entity of single bubble.
- the gas can be considered to be distributed throughout the particle and still arrive at a result that is similar to that for a single, discrete volume of gas.
- the main contribution to the increased scattering cross-section is due to the compressibility difference between gas and water.
- the backscatter coefficient is computed as the product of the resulting differential scattering cross-section and the scatterer number density. Clinical use of these nanosponges is suggested.
- Encapsulated microbubbles typically last longer than free bubbles.
- encapsulated microbubbles can also be used as drug delivery agents.
- microvessel rupture caused by insonification of thin polymer-shelled microbubbles in vivo has been suggested as a minimally invasive means for delivering colloidal particles and engineered red blood cells across the endothelial lining of a targeted tissue region
- An object of the present invention is to provide surface stabilized microbubbles.
- the surface stabilized microbubble is produced by introducing microparticles having hydrophobic surface properties and which have been stored in a gaseous environment into a liquid so that the microparticle carries with it some gas into the liquid, thereby creating a microbubble attached to or encapsulating the microparticle .
- the surface stabilized microbubble is produced by introducing microparticles with an affinity toward a specific gas and which have been stored in that gas into the liquid.
- surface stabilized microbubbles are produced by insertion of a hydrophobic surface into a medium which contains a relatively hydrophobic dissolved gas such as oxygen, or nitrogen, which spontaneously comes out of solution and forms on the hydrophobic surface.
- gas bubbles that are present or generated in the solution attach themselves to the introduced hydrophobic surface.
- gas bubbles may be generated by a variety of methods including, but not limited to, due to agitation, homogenization, sonication, decompression, phase shift, or chemical effervescence.
- Surface stabilized microbubbles of the present invention are useful as ultrasound contrast and drug delivery agents and to create ecogenic surfaces on objects to enhance ultrasonic detection of the object .
- Figure 1 shows a schematic of the in vi tro apparatus used to measure the acoustic properties of the surface stabilized microparticles of the present invention.
- a surface stabilized microbubble technique is provided to produce ultrasound contrast agents and ecogenic surfaces which enhance ultrasound detection of objects.
- This surface stabilized microbubble technique is also useful in development of novel drug delivery systems.
- the technique of the present invention utilizes microparticles having hydrophobic surface properties or with an affinity toward a specific gas. When a dry, relatively hydrophobic microparticle from a gaseous environment is introduced into a liquid such as buffer, water or blood, the particle carries with it some of the gas into the liquid, thereby creating a microbubble which attaches to or encapsulates the microparticle.
- tiny gas bubbles can spontaneously form on the surface of the microparticle from the solution.
- the gas bubble may wholly encapsulate the particle or attach/adhere itself to part of the particle.
- microparticles can be used which have an affinity for a specific gas.
- surface stabilized microbubbles can be created by storing microparticles with an affinity toward a specific gas in the specific gas and then introducing the microparticle into a liquid so that the microparticle carries with it some gas in which it was stored into the liquid so that a gas microbubble attaches to or encapsulates the microparticle.
- Microparticles useful in the present invention may be solid or hollow and may comprise organic or inorganic compounds and even living components. These can include solid or hollow microparticles or surfaces of non-biodegradable polymers such as teflon, poly vinyl alcohol, polystyrene and polyethylene and biodegradable polymers such as poly anhydrides, poly esters, starch, cellulose, and ethyl cellulose.
- the particles may include encapsulated or adhered drugs or cells such as genetically engineered cell lines which can excrete specific desired factors such as growth or necrosis factors.
- Microparticles may be spherical or irregular in shape. However, microparticles or surface coatings used in the present invention must be partially or completely coated or made up of, at least in part, a relatively hydrophobic component. Alternatively, the microparticles or surface coatings must have an affinity for a selected gas.
- the microbubble portion of the surface stabilized microbubble can be formed by any gas. Examples include, but are not limited to air, SF 6 , noble gases such as xenon, and PFCs.
- a targeting moiety such as an antibody can also be attached to the surface stabilized particle.
- surface stabilized microbubbles have backscattering characteristics which render them useful in ultrasound contrast.
- microbubbles of the present invention were tested using equal weights (0.5 grams) of microparticles with varying hydrophobicities .
- Specifically backscattering enhancement as a function of time was determined individually for starch (Sigma, Missouri, USA) , talc (Baby powder, CVS ,USA or Plastodent Inc. NY USA) and polyethylene (Shamrock Technologies Inc. NJ, USA) microparticles alone or in the presence of a surfactant.
- the level of backscattering enhancement was consistent with the extent of the particle's surface hydrophobicity. Polyethylene and talc showed excellent backscattered enhancement (>30 dB) .
- the surface stabilized microbubbles in both cases were stable at the same level of enhancement over a period of 15 minutes .
- the enhancement of polyethylene at a dose of 0.5 grams was masked by shadowing. Hence, additional tests were carried out at lower doses of 0.05 grams and 0.02 grams .
- the techniques of creating surface stabilized microbubbles from microparticles are also applicable to larger surfaces of objects such as radioactive seeds or biopsy needles. Using these techniques, ecogenic surfaces can be created to enhance the ultrasonic detection of the object.
- the preferred method of in vivo administration of surface stabilized microparticulate agents is via suspension of the lyophilized particulate surface in a physiologically acceptable buffer, followed by intravenous injection just prior to conducting an ultrasound scan.
- the microparticulates can be stored under an atmosphere of the desired gas, for example SF 6 or a PFC.
- the needle can be coated with a hydrophobic surface, and stored sterile either under vacuum or in the presence of a gas of choice.
- the vacuum stored object would be used under conditions where gas is expected to spontaneously form small microbubbles on the surface in si tu .
- the seeds would be pre-coated with the hydrophobic surface and stored sterile either in vacuum or in the presence of a gas of choice .
- Surface stabilized microbubbles are also useful in drug delivery and targeting techniques . Since the microbubbles are stabilized at the surface of a polymer or particle, this polymer/particle can comprise a matrix containing a drug by incorporation or by surface binding, or can comprise drug particle itself. Surface stabilized microbubbles comprising the drug can then be delivered to an imaged site by insonation of the surface/particle, causing the matrix to vibrate and release drug. It is also possible that the insonation will cause the particle to rupture, releasing part or all of any contents trapped within the matrix or within the hollow interior of the particle.
- Example Acoustic properties of the surface stabilized microparticles were measured in an in-vitro setup illustrated in Figure 1.
- An acrylic sample container (5 x 10 x 17.8 cm), having a 5 x 5 cm acoustic window (2) was filled with 750 ml of Phosphate buffer saline (PBS) ⁇ NaCl [8.01 grams], KC1 [0.194 grams], Na 2 HP0 4 [0.909 grams], and KH 2 P0 4 [0.191 grams] in one liter of water ⁇ , and placed inside the tank at approximately 30 mm from the back of the tank and 75 mm from the sides. The cover of the tank was fitted with a x-y positioning system
- the received signals from the transducer were fed to a digital oscilloscope, (5) , (LeCroy 9350A, LeCroy Corporation, NY, USA) .
- the digitized data from the oscilloscope were then stored and processed using Labview 4.1 (National Instruments, Austin, TX, USA) and a computer, (6) , (PowerMac 7500/132) .
- the transducer was aligned using the X and Y axis controls to obtain maximum amplitude of the signal.
- the transducer was then advanced towards the sample container by approximately 3 mm.
- the focus of the transducer lay 3 mm inside the sample container, which was approximately 7.5 ⁇ sec from the front wall echo.
- the gain of the amplifier was changed to 40 dB .
- the backscattered enhancement was recorded at every minute for 15 minutes, post administration of the agent. The results were plotted as backscattered enhancement (dB) versus time in minutes .
- Three agents namely, starch (Sigma) , talc ( Baby powder, CVS, USA or Plastodent Inc. NY, USA) and polyethylene microparticles (Shamrock Technologies Inc. USA) were chosen. Starch was the least hydrophobic, while polyethylene was the most hydrophobic of the three.
- a sample (0.5 grams) of the agent to be tested was taken and the backscattered enhancement with time was recorded. The measured amount of backscattered enhancement was consistent with the hydrophobicity of the test sample .
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU54573/00A AU5457300A (en) | 1999-06-01 | 2000-06-01 | Surface stabilized microbubbles for use in ultrasound contrast and drug deliveryagents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13696599P | 1999-06-01 | 1999-06-01 | |
US60/136,965 | 1999-06-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000072757A1 true WO2000072757A1 (en) | 2000-12-07 |
Family
ID=22475231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/015161 WO2000072757A1 (en) | 1999-06-01 | 2000-06-01 | Surface stabilized microbubbles for use in ultrasound contrast and drug delivery agents |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU5457300A (en) |
WO (1) | WO2000072757A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013013067A2 (en) * | 2011-07-19 | 2013-01-24 | Nuvox Pharma, L.L.C. | Microbubble compositions, method of making same, and method using same |
WO2015141917A1 (en) * | 2014-03-19 | 2015-09-24 | 서강대학교 산학협력단 | Dual-purpose pat/ultrasound contrast agent bound with nanoparticles containing drug and method for preparing same |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5141738A (en) * | 1983-04-15 | 1992-08-25 | Schering Aktiengesellschaft | Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof |
US5271928A (en) * | 1990-04-02 | 1993-12-21 | Sintetica S.A. | Stable microbubbles suspensions injectable into living organisms |
US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
-
2000
- 2000-06-01 AU AU54573/00A patent/AU5457300A/en not_active Abandoned
- 2000-06-01 WO PCT/US2000/015161 patent/WO2000072757A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5141738A (en) * | 1983-04-15 | 1992-08-25 | Schering Aktiengesellschaft | Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof |
US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
US5271928A (en) * | 1990-04-02 | 1993-12-21 | Sintetica S.A. | Stable microbubbles suspensions injectable into living organisms |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013013067A2 (en) * | 2011-07-19 | 2013-01-24 | Nuvox Pharma, L.L.C. | Microbubble compositions, method of making same, and method using same |
WO2013013067A3 (en) * | 2011-07-19 | 2013-04-04 | Nuvox Pharma, L.L.C. | Microbubble compositions, method of making same, and method using same |
US10279053B2 (en) | 2011-07-19 | 2019-05-07 | Nuvox Pharma Llc | Microbubble compositions, method of making same, and method using same |
WO2015141917A1 (en) * | 2014-03-19 | 2015-09-24 | 서강대학교 산학협력단 | Dual-purpose pat/ultrasound contrast agent bound with nanoparticles containing drug and method for preparing same |
KR20150109064A (en) * | 2014-03-19 | 2015-10-01 | (주)아이엠지티 | Dual-Purpose PAT/Ultrasound Contrast Agent with Nanoparticles Including Drug and Method for Preparing the Same |
KR101595795B1 (en) | 2014-03-19 | 2016-02-22 | (주)아이엠지티 | Dual-Purpose PAT/Ultrasound Contrast Agent with Nanoparticles Including Drug and Method for Preparing the Same |
US10912848B2 (en) | 2014-03-19 | 2021-02-09 | Imgt Co, Ltd. | Dual-purpose PAT/ultrasound contrast agent bound with nanoparticles containing drug and method for preparing same |
Also Published As
Publication number | Publication date |
---|---|
AU5457300A (en) | 2000-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4837663B2 (en) | Gas-filled microvesicle composition for contrast imaging | |
CA2214778C (en) | Process for the production of polymeric microparticles, microparticles that are produced according to this process as well as their use in medical diagnosis | |
US5560364A (en) | Suspended ultra-sound induced microbubble cavitation imaging | |
US8715622B2 (en) | Echogenic polymer microcapsules and nanocapsules and methods for production and use thereof | |
US5352436A (en) | Surfactant-stabilized microbubble mixtures, process for preparing and methods of using the same | |
Wheatley et al. | Comparison of in vitro and in vivo acoustic response of a novel 50: 50 PLGA contrast agent | |
US20060013771A1 (en) | Method of preparing gas-filled polymer matrix microparticles useful for echographic imaging | |
US20040258760A1 (en) | Isolated nanocapsule populations and surfactant-stabilized microcapsules and nanocapsules for diagnostic imaging and drug delivery and methods for their production | |
CN101977634A (en) | Method for the synthesis of hollow spheres | |
JP5015606B2 (en) | Ultrasound contrast agent for molecular imaging | |
EP1164936B1 (en) | A method to measure ambient fluid pressure | |
EP1390016B1 (en) | Echogenic polymer microcapsules and nanocapsules and methods for production and use thereof | |
US20100221190A1 (en) | Method for producing a particle comprising a gas core and a shell and particles thus obtained | |
CA2248739A1 (en) | Microparticles, process for their production, and their use in ultrasound diagnosis | |
AU2002307056A1 (en) | Echogenic polymer microcapsules and nanocapsules and methods for production and use thereof | |
WO2000072757A1 (en) | Surface stabilized microbubbles for use in ultrasound contrast and drug delivery agents | |
Deng | Development and characterization of a contrast agent for diagnostic ultrasound: polymer-coated microcapsules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09980134 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |